
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$20.03
+US$0.12 · +0.60%
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
前收盘价
US$20.03
+US$0.12 · +0.60%
盘后
US$20.1403
+US$0.1103 · +0.55%
10月12日 19:50 ET
盘中时间采用ET。市场数据可能有所延迟。
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
日内区间
当前US$20.03
52周区间
当前US$20.03
盘中时间采用ET。市场数据可能有所延迟。
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
日内区间
当前US$20.03
52周区间
当前US$20.03
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 30.19亿 USD | 27.94亿 USD | 23.94亿 USD | 22.12亿 USD | 20.94亿 USD |
| 销货成本 | 18.83亿 USD | 17.74亿 USD | 15.3亿 USD | 14.21亿 USD | 13.25亿 USD |
| 毛利 | 11.36亿 USD | 10.2亿 USD | 8.64亿 USD | 7.91亿 USD | 7.69亿 USD |
| 研究与开发 | 1.86亿 USD | 1.91亿 USD | 1.95亿 USD | 2.09亿 USD | 2.1亿 USD |
| 销售、一般及管理费用 | 5.27亿 USD | 4.76亿 USD | 4.3亿 USD | 4亿 USD | 3.66亿 USD |
| 营业费用 | 7.13亿 USD | 7.71亿 USD | 6.59亿 USD | 8.86亿 USD | 6.16亿 USD |
| 利息支出 | 2.41亿 USD | 2.59亿 USD | 2.11亿 USD | 1.58亿 USD | 1.36亿 USD |
| 折旧和摊销 | 2.24亿 USD | 2.36亿 USD | 2.29亿 USD | 2.4亿 USD | 2.33亿 USD |
| 营业利润 | 4.23亿 USD | 2.49亿 USD | 2.04亿 USD | −9492.8万 USD | 1.53亿 USD |
| 净利润 | 7205.7万 USD | −1.17亿 USD | −8399.3万 USD | −1.3亿 USD | 1062.4万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$23.20
上涨空间 15.83%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI9742.51万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM8073.11万0.10%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB7044.82万0.04%1853亿 USD0.03%US$288.16-0.46%
Dimensional - US Small Cap ETFDFAS4760.84万0.14%338.69亿 USD0.31%US$78.17-0.23%
Vanguard Morningstar Small-Cap Value ETFVBR4479.13万0.07%682亿 USD0.05%US$234.71+0.12%
Invesco S&P SmallCap Momentum ETFXSMO4309.09万1.50%28.69亿 USD0.35%US$81.31-0.54%
Vanguard Extended Market ETFVXF3497.66万0.04%954亿 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM3385.71万0.21%157.12亿 USD0.03%US$53.42-0.06%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Dimensional - US Small Cap ETFDFAS
Vanguard Morningstar Small-Cap Value ETFVBR
Invesco S&P SmallCap Momentum ETFXSMO
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。